Lab
Hermes Health Labs
Hermes Health Labs was paid $1.28M by Medicaid between Oct 2022 and Nov 2023, across 26 billing codes. Its largest line is 87637, Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV — 87% of everything it billed.
33Billing provider infoHERMES HEALTH LABS
SCOTTSDALE, AZ 85254
SCOTTSDALE, AZ 85254
33aNPI1700502184assigned 10/17/2022
33bProvider typeClinical Medical Laboratory
28Total paid$1.28M
24GClaims14,064
24DCodes billed26
24AFirst – last monthOct 2022 – Nov 2023
Compared with peers
Next to other Clinical Medical Laboratory providers in Arizona
Rank by total paid#20 of 67
Median peer was paid$89K
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 86 | $1K | |
| 2023 | 13,978 | $1.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 87% | 8,754 | 1,531 | $1.11M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 10% | 2,669 | 842 | $130K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.3% | 436 | 251 | $30K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 424 | 245 | $8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 161 | 102 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 157 | 157 | $789.28 |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 180 | 176 | $514.82 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 160 | 160 | $204.54 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 209 | 208 | $203.34 |
| 84681 | <1% | 12 | 12 | $194.15 | |
| 83090 | <1% | 12 | 12 | $178.08 | |
| 80061 | Lipid panel | <1% | 136 | 135 | $148.46 |
14 more codes
| 83525 | <1% | 27 | $130.78 | |
| 80053 | Comprehensive metabolic panel | <1% | 169 | $64.51 |
| 84153 | <1% | 12 | $16.35 | |
| 84439 | <1% | 31 | $7.83 | |
| 84481 | 0% | 50 | $0.00 | |
| 83970 | 0% | 26 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 56 | $0.00 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 0% | 160 | $0.00 |
| 86376 | 0% | 33 | $0.00 | |
| 84436 | 0% | 14 | $0.00 | |
| 86800 | 0% | 33 | $0.00 | |
| 84479 | 0% | 27 | $0.00 | |
| 81015 | 0% | 32 | $0.00 | |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 0% | 84 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMYERS, CHRIS (CEO)
| Provider | Location | Paid |
|---|---|---|
| Vanguard Laboratory Innovations | Tulsa, OK | $63K |
| No 206 LLC | Marina Del Rey, CA | $536.76 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.